Brief: ADC Therapeutics Doses First Patient In Phase 1B Clinical Trial Of ADCT-601

ADC Therapeutics SA

27/07/2022 12:23

July 27 (Reuters) - ADC Therapeutics SA  ADCT.N :
    * ADC THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1B CLINICAL
TRIAL
OF ADCT-601 TARGETING AXL AS A SINGLE AGENT AND IN COMBINATION
WITH GEMCITABINE IN ADVANCED SOLID TUMORS

Source text for Eikon:  ID:nBw6rWH7Pa 
Further company coverage:  ADCT.N 

 ((Reuters.Briefs@thomsonreuters.com;))